EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Inclusion Criteria: * Women aged 18-70； * 0-1 for ECOG； * Unilateral invasive carcinoma confirmed by histology (regardless of pathological type)； * No gross or microscopic tumor remains after surgical resection； * Early breast cancer, pathologically confirmed as HER2 positive; HER2 positive definition: Immunohistochemical HER2 3+ or FISH/CISH test positive (with amplification) is defined as HER2 positive； * Postoperative pathological stage pT1-4N1-3M0； * Did not receive neoadjuvant chemotherapy in the past； * The longest period from surgery to randomization was not more than 8 weeks, and no adjuvant therapy had been received after surgery； * No peripheral neuropathy； * Good postoperative recovery, at least 1 week interval between operation； * The major organs function normally, that is, meet the following criteria: (1) The standard of blood routine examination shall meet: HB ≥90 g/L (no blood transfusion within 14 days); ANC ≥1.5×109 /L; PLT ≥100×109 /L; (2) Biochemical examination should meet the following standards: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3 x ULN; Serum Cr ≤1.5×ULN； * Contraception during treatment for women of reproductive age； * Cardiac function: LVEF\>50% for ultrasound examination； * The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up。 Exclusion Criteria: * Bilateral breast cancer or carcinoma in situ DCIS/LCIS； * Have received chemotherapy for advanced disease； * Transfer of any part； * If any tumor \>T4a (accompanied by skin invasion, mass adhesion fixation, inflammatory breast cancer)； * Patients with clinical or imaging suspicion of malignancy on the opposite breast but not confirmed, requiring biopsy； * Have received neoadjuvant therapy, including chemotherapy, radiotherapy and endocrine therapy； * Malignant neoplasms (other than basal cell carcinoma of the skin and carcinoma in situ of the cervix), including contralateral breast cancer, within the previous 5 years； * The patient has been enrolled in other clinical trials； * Patients with severe systemic disease and/or uncontrolled infection were unable to be enrolled in the study； * LVEF\<50% (cardiac ultrasound)； * Severe cardiovascular and cerebrovascular disease (e.g., unstable angina, chronic heart failure, uncontrolled hypertension \>150/90mmgh, myocardial infarction or cerebrovascular accident) within 6 months prior to randomization； * Known allergy to related drugs； * Women of childbearing age refuse contraception during treatment and within 8 weeks after completion of treatment； * Pregnant and lactating women； * Those who tested positive for pregnancy before taking the drug after joining the trial； * Mental illness, cognitive impairment, inability to understand the trial protocol and side effects, inability to complete the trial protocol and follow-up workers ；(systematic evaluation is required before trial enrollment)； * Persons without personal freedom and independent capacity for civil conduct。